煤炭 2025 年 5 月 7 日 潞安环能(601699.SH) 煤价下行至底部区间，静待耗煤旺季拐点来临 推荐（维持） 股价：10.97 元 主要数据 | 行业 | 煤炭 | | --- | --- | | 公司网址 | www.luanhn.com | | 大股东/持股 | 山西潞安矿业集团 / 61.44% | | 实际控制人 | 山西省国资委 | | 总股本(百万股) | 2991 | | 流通 A 股(百万股) | 2991 | | 流通 B/H 股(百万股) | -- | | 总市值（亿元） | 328 | | 流通 A 股市值(亿元) | 328 | | 每股净资产(元) | 15.79 | | 资产负债率(%) | 38.27 | 行情走势图 -60% -40% -20% 0% 20% 40% 24-04 24-05 24-06 24-07 24-08 24-09 24-10 24-11 24-12 25-01 25-02 25-03 25-04 潞安环能 沪深300 相关研究报告 《潞安环能(601699.SH)公司首次覆盖报告：资金 增厚 债务收窄，价有弹性量增可期》2024-11-18 ...

Investment Rating - The report maintains an "Outperform" rating for the industry [1] Core Insights - Wind turbine prices continue to rise steadily, with the average bidding price reaching 1590 CNY/kW in March 2025, up 4.1% from December 2024 and 7.8% from September 2024 [5][10] - The domestic hydrogen energy industry is expected to accelerate its development, supported by new policies and guidelines from the government [6] Wind Power - Wind turbine average bidding prices have shown a recovery trend since Q4 2024, driven by self-discipline agreements among major wind turbine manufacturers and adjustments in bidding strategies by developers [11] - The wind power sector's PE_TTM valuation is approximately 18.37 times as of the latest week [12] - The report anticipates that the profitability of wind turbine manufacturers will improve significantly in 2026 due to a more favorable supply-demand situation for components [11][12] Photovoltaics - Major photovoltaic companies are facing significant losses due to high fixed asset depreciation, with TCL Zhonghuan reporting a net loss of 10.806 billion CNY in 2024 [6] - The overall PE_TTM for the photovoltaic sector is around 30.55 times, indicating a challenging environment for profitability [4] - The report suggests that while asset impairment impacts may decrease, the large scale of fixed asset depreciation will continue to pose challenges for profitability in the photovoltaic manufacturing sector [6] Energy Storage & Hydrogen Energy - The domestic hydrogen energy industry is poised for rapid growth, with new policies expected to support its development in various transportation sectors [6] - The hydrogen energy sector's PE_TTM is currently at 34.47 times, reflecting investor interest and potential growth [4] - The report highlights the importance of upcoming policies that will further promote the hydrogen energy industry [6] Investment Recommendations - For wind power, focus on companies like Mingyang Smart Energy, Dongfang Cable, and Yaxing Anchor Chain, particularly in offshore wind power [6] - In photovoltaics, attention is drawn to companies such as Dier Laser, Longi Green Energy, and Aiko Solar, with a focus on the BC battery industry trend [6] - In energy storage, key players include Sungrow Power Supply and Shuneng Electric, with a strong demand outlook [6] - For hydrogen energy, companies like Huaguang Huaneng and Yihua Tong are recommended for their positions in the electrolyzer and fuel cell systems [6]

Investment Rating - The report maintains a "Strong Buy" rating for the oil and petrochemical sector [1]. Core Insights - OPEC+ continues to increase production, potentially using price drops to constrain overproduction by member countries, which may lead to downward pressure on oil prices [6][7]. - The domestic oil companies are expected to show resilience due to integrated operations and diversified energy sources, particularly focusing on offshore oil and gas resources [7]. - The fluorochemical sector is benefiting from national subsidies driving domestic demand, with refrigerant prices continuing to rise [6][7]. Summary by Sections Oil and Petrochemicals - OPEC+ agreed to continue increasing production by 411,000 barrels per day in June, consistent with previous announcements and market expectations [6][7]. - Recent geopolitical developments, including a potential ceasefire in Ukraine and discussions regarding Iran's nuclear program, have reduced upward pressure on oil prices [6][7]. - The U.S. labor market showed strong performance with 177,000 new jobs added in April, which may affect Federal Reserve interest rate decisions [6]. Fluorochemicals - National subsidies are driving strong growth in domestic demand for refrigerants, with prices for R32 and R134a rising by 500 yuan per ton as of April 30 [6]. - The production of second-generation refrigerants is expected to decrease, while third-generation refrigerants will see limited quota increases, leading to a favorable supply-demand balance [6][7]. Semiconductor Materials - The semiconductor materials sector is experiencing a positive trend with inventory reduction and improving end-market conditions, suggesting potential for upward movement in the industry index [7].

其 他 报 告 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3316 | 1.13 | -0.49 | | 深证成份指数 | 10082 | 1.84 | -0.17 | | 沪深300指数 | 3809 | 1.01 | -0.43 | | 创业板指数 | 1986 | 1.97 | 0.04 | | 上证国债指数 | 225 | 0.03 | 0.11 | | 上证基金指数 | 6856 | 1.24 | -0.04 | | | | 资料来源:同花顺iFinD | | | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 22663 | 0.70 | 2.38 | | 中国香港国企指数 | 8262 | 0.37 | 1.86 | | 中国台湾加权指数 | 20523 | -0.05 | 4.60 | | 道琼斯指数 | 41219 | -0.24 | 3.00 | | ...

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry Core Insights - The pharmaceutical sector has experienced three major market trends since 2018: 1) The CXO sector led the market from 2019 to 2021 2) The traditional Chinese medicine sector was boosted by policy support and increased demand from 2021 to 2023 3) The innovative drug sector has been driving the market since 2024 [2][5] - The current policies supporting the innovative drug sector are clear and defined, with commercial insurance directories expected to enhance accessibility for patients [2][25] - The valuation of pharmaceutical stocks and the proportion of public funds heavily invested in the pharmaceutical sector are at historical lows, indicating potential investment opportunities [2][29] Summary by Sections Pharmaceutical Market Review - The pharmaceutical and biotechnology industry has undergone three significant market phases since 2018: 1) The CXO sector from 2019 to 2021 2) The traditional Chinese medicine sector from 2021 to 2023 3) The innovative drug sector from 2024 to present [5][22] Pharmaceutical Fund Holdings - Pharmaceutical theme funds and overall market funds have shifted their investment focus in line with market trends, moving from generic drugs to the CXO sector, and now heavily investing in innovative drugs while reducing exposure to traditional Chinese medicine [2][38] - As of the first quarter of 2025, 24 pharmaceutical theme funds have over 30% of their holdings in innovative drugs, indicating a strong focus on this sector [50] Pharmaceutical Fund Manager Case Studies - Fund managers such as Zhou Sicong and Jiang Qi adopt different investment styles, focusing on growth potential and market cycles, with a significant emphasis on high-concentration holdings in promising sectors [2][58]

证券研究报告 【平安证券】利率债5月报：关注利差压缩行情的相关机会 证券分析师 刘璐 投资咨询资格编号：S1060519060001 郑子辰 投资咨询资格编号：S1060521090001 2025年5月6日 请务必阅读正文后免责条款 摘要 美元资产受冲击，国内债券上涨、股市呈现韧性。4月以来全球贸易不确定性加剧，全球避险情绪升温、资产波动加大。整体看黄金价格大幅上涨， 资金流出美国导致美国股债汇承压；同时机构杠杆交易平仓进一步加剧美债在4%-4.5%之间波动。国内方面，债券上涨、股市呈现韧性。月初资金 利率快速下行20BP，10年国债收益率迅速下移15BP至1.65%附近，4月下旬以后各资产波动收敛。一季度经济呈现"开门红"，债市多头等待货币宽 松预期的兑现，债市空头则认为货币增量落地前赔率有限，多空力量比较均衡。机构行为方面，4月大行配债力度有所减弱，农商行进攻久期，基 金主要加仓信用债，险资小幅放缓配债节奏，挑选有估值优势的长久期地方债，理财规模下降略大于季节性，主要配置同业存单，管控思路相对 稳健。 存款利率降息如何影响债市？我们梳理了22年以来每一轮大行存款利率降息情况，规律如下：（1）时间上，每年 ...

策略配置 策 略 动 态 跟 踪 报 告 2024 年年报及 2025 年一季报业绩综述 实体企业盈利增速转正，AI 科技板块景气居前 证券分析师 | 魏伟 | 投资咨询资格编号 | | --- | --- | | | S1060513060001 | | | BOT313 | | | WEIWEI170@pingan.com.cn | | 张亚婕 | 投资咨询资格编号 | | | S1060517110001 | | | ZHANGYAJIE976@pingan.com.cn | | 蒋炯楠 | 投资咨询资格编号 | | | S1060524120002 | | | JIANGJIONGNAN597@pingan.com.cn | 平安观点： 2025 年 5 月 6 日 策 略 报 告 证 券 研 究 报 告 整体盈利：2025Q1 全 A 非金融盈利增速由负转正。25Q1 全 A/全 A 非金融净 利润累计同比增速为 3.5%/4.2%，较 24Q4 提升 6.4pct/17.2pct。2024 年报披 露实体企业境外业务收入同比增长 8.0%，占营收比重较 2023 年提升 1.2pct至 14.3% ...

Investment Rating - The report maintains a "Recommended" rating for the company [9] Core Views - The company's revenue for Q1 2025 reached 606 million yuan, representing a year-on-year increase of 20.05%, with a net profit attributable to shareholders of 62 million yuan, up 272.28% [4] - The front-end business, including molecular building blocks, tool compounds, and biological reagents, achieved revenue of 1.499 billion yuan in 2024, a growth of 32.41%, with a gross margin of 62.21%, reflecting improved revenue structure and profitability due to successful overseas sales and logistics initiatives [4][5] - The back-end business, which includes APIs, intermediates, and formulations, generated revenue of 755 million yuan in 2024, a modest increase of 2.49%, with a gross margin of 20.05%, indicating a more competitive environment [4][5] Financial Performance Summary - The company is projected to achieve revenues of 2.27 billion yuan in 2024, 2.73 billion yuan in 2025, and 3.28 billion yuan in 2026, with year-on-year growth rates of 20.8%, 20.2%, and 20.2% respectively [7] - Net profit is expected to rise from 202 million yuan in 2024 to 244 million yuan in 2025, and further to 333 million yuan in 2026, with corresponding year-on-year growth rates of 58.2%, 21.1%, and 36.4% [7] - The gross margin is anticipated to improve from 48.0% in 2024 to 51.4% by 2027, while the net margin is expected to increase from 8.9% to 11.3% over the same period [11] Capacity and Utilization - The company has seen an increase in utilization rates across its various bases, with several facilities, including the Hefei R&D center and Yantai base, now fully operational [6] - The Chongqing antibody-drug conjugate (ADC) base commenced production in Q1 2025, expanding the company's capabilities across the entire supply chain [6]

证券研究报告 社会服务行业周报 五一出行"多点开花"， 即时零售热度升级 社会服务行业 强于大市（维持） 核心摘要 平安证券研究所 新消费团队 分析师：胡琼方 S1060524010002（证券投资咨询） 邮箱：huqiongfang722@pingan.com.cn 2025年05月06日 请务必阅读正文后免责条款 3 据人民日报客户端，5月1日至5日，预计全社会跨区域人员流动量累计14.67亿人次，日均2.93亿人次，同比增长 8.0%。其中：铁路客运量累计10169.2万人次，日均2033.8万人次，同比增长10.8%。公路人员流动量(包括高速公路 及普通国省道非营业性小客车人员出行量、公路营业性客运量)累计13.45亿人次，日均2.69亿人次，同比增长7.6%。 水路客运量累计868.9万人次，日均173.8万人次，同比增长24.9%。民航客运量累计1114.3万人次，日均222.9万人次， 同比增长11.8%。 据携程黑板报公众号，五一假期长线游目的地表现亮眼，青海、新疆、宁夏等地景区门票销售额同比激增1-2倍；亲 子家庭与携宠出游"双线并进"；自驾游市场"量价齐升" ，异地出行占比达85%；邮轮游 ...

Investment Rating - The industry investment rating is "Outperform the Market" [1][24]. Core Insights - The computer industry is expected to achieve stable revenue growth in 2024, with a significant improvement in profits in the first quarter of 2025. As of the end of April, 360 A-share listed companies in the computer sector have released their 2024 annual reports and 2025 Q1 reports. In 2024, the overall revenue of these companies is projected to reach CNY 12,492.99 billion, a year-on-year increase of 4.76%, while net profit is expected to decline by 49.91% to CNY 163.28 billion. In Q1 2025, revenue is anticipated to grow rapidly, achieving CNY 2,818.69 billion, a year-on-year increase of 15.92%, with net profit rising significantly by 652.15% to CNY 23.29 billion [3][6][7]. Summary by Sections Industry Performance - In 2024, the computer equipment sector (89 companies) is expected to achieve revenue of CNY 4,130.51 billion, a year-on-year increase of 12.74%, and a net profit of CNY 239.41 billion, up 10.96%. The software development sector (139 companies) is projected to generate CNY 3,472.89 billion in revenue, a slight increase of 0.92%, but a net loss of CNY 22.92 billion. The IT services sector (132 companies) is expected to have revenue of CNY 4,889.59 billion, a growth of 1.44%, with a net loss of CNY 53.22 billion [6][7]. Q1 2025 Performance - In Q1 2025, the computer equipment sector is expected to achieve revenue of CNY 1,059.13 billion, a year-on-year increase of 39.27%, and a net profit of CNY 43.18 billion, up 12.03%. The software development sector is projected to generate CNY 677.01 billion in revenue, a slight increase of 0.86%, with a net loss of CNY 23.79 billion. The IT services sector is expected to achieve revenue of CNY 1,082.56 billion, a growth of 8.28%, with a net profit of CNY 3.90 billion [7]. Key Company Announcements - Notable announcements include Industrial Fulian reporting a 2024 revenue of CNY 6,091.35 billion, a year-on-year increase of 27.88%, and a Q1 2025 revenue of CNY 1,604.15 billion, up 35.16%. Inspur Information reported a Q1 2025 revenue of CNY 468.58 billion, a significant increase of 165.31%. Unisplendour reported a 2024 revenue of CNY 790.24 billion, a growth of 2.22%, and a Q1 2025 revenue of CNY 207.90 billion, up 22.25% [12][14]. Market Performance - The computer industry index rose by 2.47% last week, outperforming the CSI 300 index, which fell by 0.43%. The overall P/E ratio for the computer industry is 50.6 times, with 262 out of 360 A-share stocks rising in price [15][17]. Investment Recommendations - The report suggests focusing on several sectors: 1. **New Infrastructure**: Recommended companies include Haiguang Information, Longxin Zhongke, and others. 2. **Huawei Supply Chain**: Recommended companies include Digital China and others. 3. **AI Sector**: Strong recommendations for Zhongke Chuangda and others. 4. **Low-altitude Economy**: Recommended companies include Daotong Technology and others. 5. **Financial IT**: Strong recommendation for Hengsheng Electronics and others [20].